GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » Capex-to-Revenue

AXGN (Axogen) Capex-to-Revenue : 0.02 (As of Sep. 2024)


View and export this data going back to 1986. Start your Free Trial

What is Axogen Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Axogen's Capital Expenditure for the three months ended in Sep. 2024 was $-1.14 Mil. Its Revenue for the three months ended in Sep. 2024 was $48.64 Mil.

Hence, Axogen's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.02.


Axogen Capex-to-Revenue Historical Data

The historical data trend for Axogen's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axogen Capex-to-Revenue Chart

Axogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.20 0.22 0.15 0.09

Axogen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.04 0.03 0.03 0.02

Competitive Comparison of Axogen's Capex-to-Revenue

For the Medical Devices subindustry, Axogen's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axogen's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axogen's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Axogen's Capex-to-Revenue falls into.



Axogen Capex-to-Revenue Calculation

Axogen's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-14.918) / 159.012
=0.09

Axogen's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.138) / 48.644
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axogen  (NAS:AXGN) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Axogen Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Axogen's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Axogen Business Description

Traded in Other Exchanges
Address
13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Executives
Angelo Scopelianos officer: Chief R&D Officer C/O AXOGEN, INC., 13631 PROGRESS BOULEVARD - SUITE 400, ALACHUA FL 32615
Karen L. Zaderej director, officer: CEO AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Erick Wayne Devinney officer: VP, Clinical&Translational Sc 13631 PROGRESS BLVD SUITE 400, ALACHUA FL 32615
Michael Patrick Donovan officer: VP Operations C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Peter J Mariani officer: Chief Financial Officer C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Burke William P. Mr. director HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Marc A Began officer: EVP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall director 13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Maria D. Martinez officer: Chief Human Resources Officer C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Mark Stephen Gold director 13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876